The event began with opening statements from each candidate, followed by discussions regarding top concerns in the community.

Over 400 bicyclists departed Simpsonville, SC Friday morning, and headed towards Charleston, SC, beginning the first day of a ...

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...

Empowering, participatory approaches are needed to improve quality of life and health outcomes for people with dementia, write Emily Ong and colleagues Dementia is the seventh leading cause of death ...

INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

Recognizing the difference between normal aging and early cognitive decline is crucial for timely intervention. Subtle ...

The lumipulse blood test brings renewed hope for earlier diagnosis and treatment for millions of people facing the uncertainty of Alzheimer's disease and other dementias.

The first Alzheimer's blood test cleared by the Food And Drug Administration is poised to change the way doctors diagnose and treat the disease.

The test may make it easier to identify whether people with memory and thinking problems have Alzheimer’s or not.

The Lumipulse blood test identifies the presence of amyloid plaques, a hallmark of Alzheimer’s disease that impairs normal brain function.

Research shows that NRTIs, antiviral drugs used for HIV, could prevent Alzheimer's by blocking inflammasomes, offering a promising path for drug repurposing.